Catalys Pacific, LLC has filed a Form 13F-HR with the U.S. Securities and Exchange Commission, disclosing its equity securities portfolio as of the close of business on September 30, 2026.
The filing lists two companies held by the firm during the specified period. The largest holding is Mineralys Therapeutics, Inc., a company listed under ticker symbol COM 603170101. The filing indicates a total beneficial ownership of 19,600,188 shares, with all voting and dispositive rights held by the sole beneficiary.
The second disclosed holding is Phathom Pharmaceuticals, Inc., listed under ticker symbol COM 71722W107. The filing reports ownership of 1,882,039 shares, with voting and investment power held by the sole beneficiary.
The report was signed by Managing Director N. Brian Taylor Slingsby on October 28, 2026, and was filed on the same day.
